Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.72 |
| ▸ | MEN1 | O00255 | 1/20 | 0.72 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.72 |
| ▸ | RAB9A | P51151 | 1/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.72 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.72 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.72 |
| ▸ | CA12 | O43570 | 1/20 | 0.64 |
| ▸ | CA1 | P00915 | 1/20 | 0.64 |
| ▸ | CA2 | P00918 | 1/20 | 0.64 |
| ▸ | CA9 | Q16790 | 1/20 | 0.64 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.63 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.63 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4034058 | 0.89 | ALDH1A1 (0.62) | NPC1MEN1EPHX2RAB9AKMT2A | |
| SCHEMBL5177353 | 0.85 | NPC1 (0.60) | NPC1MEN1EPHX2RAB9AKMT2A | |
| SCHEMBL4155043 | 0.85 | ALDH1A1 (0.54) | NPC1MEN1EPHX2RAB9AKMT2A | |
| SCHEMBL7302137 | 0.84 | EPHX2 (1.00) | NPC1MEN1EPHX2RAB9AKMT2A | |
| SCHEMBL5188912 | 0.84 | NR1H4 (0.58) | NPC1MEN1EPHX2RAB9AKMT2A | |
| SCHEMBL5862101 | 0.84 | NPC1 (1.00) | NPC1MEN1RAB9AKMT2AL3MBTL1 | |
| SCHEMBL28497417 | 0.84 | NPC1 (1.00) | NPC1MEN1RAB9AKMT2AL3MBTL1 | |
| SCHEMBL3278159 | 0.84 | LMNA (0.68) | NPC1MEN1EPHX2RAB9AKMT2A | |
| SCHEMBL3271866 | 0.84 | KMT2A (0.68) | NPC1MEN1EPHX2RAB9AKMT2A | |
| SCHEMBL4027739 | 0.84 | ESRRG (0.74) | EPHX2NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090171091-A1 | COMPOUNDS SUITABLE AS MODULATORS OF HDL | CADILA HEALTHCARE LIMITED (IN) | 2009-07-02 | — | — | US | claimed |
| US-20090171091-A1 | COMPOUNDS SUITABLE AS MODULATORS OF HDL | CADILA HEALTHCARE LIMITED (IN) | 2009-07-02 | — | — | US | disclosed |
| US-7259183-B2 | Indole, indazole and indoline derivatives as CETP inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2007-08-21 | — | — | US | disclosed |
| EP-1776338-A1 | INDOLE, INDAZOLE OR INDOLINE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2007-04-25 | — | — | EP | disclosed |
| US-20060030613-A1 | Indole, indazole and indoline derivatives as CETP inhibitors | F. HOFFMANN-LA ROCHE AG (CH) | 2006-02-09 | — | — | US | disclosed |
| WO-2006013048-A1 | INDOLE, INDAZOLE OR INDOLINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2006-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030613-A1 | Indole, indazole and indoline derivatives as CETP inhibitors | CETP, NAT1, MTTP | NPC1 6/4885MEN1 2604/4885EPHX2 3692/4885 |
| US-20090171091-A1 | COMPOUNDS SUITABLE AS MODULATORS OF HDL | CETP, APOB, HDLBP | NPC1 11/4885MEN1 1778/4885EPHX2 2374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.